With this information, the next stage will be to progress the drug closer to patients, and potentially seek a commercial partner that may fund clinical trials.
“We are extremely grateful for the generosity of this donor, who has enabled an exciting project to continue, which we hope will one day benefit people with cancer,” Associate Professor Lessene said.